FDA Antimicrobial Development Draft Guidances Withdrawn Under Rejuvenation Initiative
This article was originally published in Pharmaceutical Approvals Monthly
FDA says the 13 guidances are out of date and of no use to industry; a number of others covering various topics also will be revised or finalized.
You may also be interested in...
FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.
Given the enthusiasm for the new advisory committee within the rare disease community, the need for an extended deadline is somewhat surprising. FDA has not yet determined when the chair and members of the new panel will be named.
Oncology Center of Excellence director said clinical trial participation may increase if the research questions are ‘significant to answer.’